<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9740">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034471</url>
  </required_header>
  <id_info>
    <org_study_id>1228/2020</org_study_id>
    <nct_id>NCT05034471</nct_id>
  </id_info>
  <brief_title>Mi-STITCH™ and Mi-KNOT™ Device Technologies - Improvement of Mitral Valve Repair</brief_title>
  <official_title>Mi-STITCH™ and Mi-KNOT™ Device Technologies Improvement of Minimally Invasive Mitral Valve Repair - A Single-center, Pilot Clinical Safety &amp; Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LSI SOLUTIONS, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to analyze the safety and efficacy of a novel device for&#xD;
      minimally invasive mitral valve repair. Data of the early and intermediate postoperative&#xD;
      period will be collected within routine clinical follow-up in order to assess morbidity and&#xD;
      mortality as well as echocardiographic parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a clinical, single-center pilot-study to evaluate safety and performance of a&#xD;
      novel device in minimally invasive mitral valve surgery. Twelve (12) patients with mitral&#xD;
      valve regurgitation planned for surgery at Vienna General Hospital (AKH) will be enrolled in&#xD;
      the study considering inclusion and exclusion criteria. Mitral valve repair is achieved by&#xD;
      replacing the chordae tendinea with expanded polytetrafluoroethylene (ePTFE) sutures either&#xD;
      with or without concomitant procedures, such as annuloplasty, resection, or gap closure.&#xD;
      These ePTFE sutures are placed between a mitral leaflet and the corresponding papillary&#xD;
      muscle using a novel suturing device (Mi-Stitch™). By adjusting the length of the suture, the&#xD;
      appropriate coaptation is achieved and prolapse is avoided - resulting in an adequate seal of&#xD;
      the valve. The procedure will be assessed according to the primary safety endpoint (30 day&#xD;
      mortality) as well as the implantation time. Likewise midterm safety endpoints at 12 months&#xD;
      (mortality and observed rate of serious adverse events [SAE]) and procedural times will be&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary safety endpoint - 30day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30 day Mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint - Implantation Time</measure>
    <time_frame>intraoperative</time_frame>
    <description>Defined as the period from start of valve assessment until the completion of the repair</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoints - Mortality</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety endpoints - Rate of SAEs</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>Rate of serious adverse events according to the current EN ISO 14155 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints - Procedural times</measure>
    <time_frame>intraoperative</time_frame>
    <description>Surgical time, aortic cross-clamp (ACC) time, cardiopulmonary bypass (CPB) time and time from first suture bite on mitral leaflet to final suture cutting and knot crimping on the papillary muscle (for each chord)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Residual mitral valve regurgitation</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>Degree of mitral valve regurgitation (MR) at 1 and 6 months.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Mitral Valve Repair with Novel Device Technologies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will undergo mitral valve repair by replacing the chordae tendinea with ePTFE single loop sutures using novel suturing devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mi-Chord™ Device Technologies</intervention_name>
    <description>Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.</description>
    <arm_group_label>Mitral Valve Repair with Novel Device Technologies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe primary mitral valve regurgitation according to current guidelines with&#xD;
             indication for mitral valve repair&#xD;
&#xD;
          -  With or without concomitant procedures such as: coronary artery bypass grafting&#xD;
             (CABG), other valve repair/replacement, pacemaker implantation, exclusion of left&#xD;
             appendage and MAZE (or PVI) procedure, aortic procedures&#xD;
&#xD;
          -  Euroscore II &lt; 8&#xD;
&#xD;
          -  Left ventricle ejection fraction &gt; 35%&#xD;
&#xD;
          -  Life expectancy above 1 year after the intervention based on operator assessment&#xD;
&#xD;
          -  Willing to sign informed consent&#xD;
&#xD;
          -  Willing to undergo all medical follow-ups necessary for the clinical investigations&#xD;
             until study termination (echocardiography, blood tests, physical investigation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Active endocarditis or myocarditis&#xD;
&#xD;
          -  Previous cardiac surgery&#xD;
&#xD;
          -  Heavily calcified mitral valve annulus&#xD;
&#xD;
          -  Severe mitral stenosis&#xD;
&#xD;
          -  Female pregnant patients&#xD;
&#xD;
          -  Emergency procedures&#xD;
&#xD;
          -  Patient not able to read or understand informed consent&#xD;
&#xD;
          -  Patient not willing to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Andreas, MD, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiac Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Andreas, MD, PhD, MBA</last_name>
    <phone>+43 1 40400 52620</phone>
    <email>martin.andreas@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Werner, MD</last_name>
    <phone>+43 1 40400 52620</phone>
    <email>paul.werner@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Andreas, MD, PhD, MBA</last_name>
      <phone>+43 1 40400 52620</phone>
      <email>martin.andreas@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Paul Werner, MD</last_name>
      <phone>+43 1 40400 52620</phone>
      <email>paul.werner@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Andreas, MD, PhD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Martin Andreas, M.D.</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr. Martin ANDREAS, MBA, PhD, MEBCTS</investigator_title>
  </responsible_party>
  <keyword>minimal invasive surgery</keyword>
  <keyword>novel surgical device</keyword>
  <keyword>mitral valve repair</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

